Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01531387Phase 3Terminated

Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)

Role: collaborator

NCT00646126Phase 3Completed

Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission

Role: lead

NCT00440752Completed

The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance

Role: lead

NCT00330902Phase 3Completed

Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan

Role: collaborator

All 4 trials loaded